Radius Health (RDUS) – Press Releases
-
Radius Recycling Reports Second Quarter Fiscal 2024 Financial Results
-
Second Quarter Fiscal 2024 Preliminary Results and Announcement of Earnings Date
-
Radius Recycling Named One of the 2024 World’s Most Ethical Companies
-
Radius Recycling Reports First Quarter Fiscal 2024 Financial Results
-
Radius Recycling Announces First Quarter Fiscal 2024 Earnings Date and Webcast Details
-
Radius Recycling Publishes Fiscal Year 2023 Sustainability Report
-
Radius Recycling Executive Included on TIME100 Climate List of the 100 Most Influential Leaders Driving Business Climate Action
-
Radius Recycling Reports Fourth Quarter and Fiscal 2023 Financial Results
-
Radius Recycling Announces Fourth Quarter and Fiscal 2023 Earnings Date and Webcast Details
-
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
-
Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
-
Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
-
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
-
Velan-Repertoire to Withdraw Director Nominations Due to Pending Sale of Radius Health
-
Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium
-
Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium
-
Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome
-
Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome
-
Velan-Repertoire Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square Capital
-
Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital
-
Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital
-
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
-
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
-
Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
-
Velan-Repertoire Releases Detailed Presentation on the Need for Board Change at Radius Health and Sends Letter to Stockholders
-
Rubric Capital Management Sends Letter to Radius Health Board of Directors
-
Velan-Repertoire Responds to Misleading Characterizations by the Radius Board
-
Radius Health Expands Non-US Market Footprint for TYMLOS
-
Radius Health Expands Non-US Market Footprint for TYMLOS
-
Velan-Repertoire Group Files Definitive Proxy Materials in Connection With Radius Health 2022 Annual Meeting
-
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Radius Files Definitive Proxy and Mails Letter to Stockholders
-
Radius Files Definitive Proxy and Mails Letter to Stockholders
-
Radius Health Update on Abaloparatide Transdermal System
-
Radius Health Update on Abaloparatide Transdermal System
-
Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors
-
Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors
-
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
-
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
-
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
-
Radius Health, Inc. First Quarter 2022 Results
-
Radius Health, Inc. First Quarter 2022 Results
-
Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022
-
Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022
-
Radius Provides Agenda for Today’s R&D Webcast
-
Radius Provides Agenda for Today’s R&D Webcast
-
Radius Health Announces Leadership Appointments
-
Radius Health Announces Leadership Appointments
Back to RDUS Stock Lookup
